<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作為您在 Google 上的首選新聞來源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>週四，Propanc Biopharma, Inc. (PPCB) 宣佈其董事會已批准一項股票回購計劃，授權公司回購最多 500 萬美元的普通股。</p>
<p>公司預計該計劃將使股東能夠繼續增加對其基礎資產的擁有權，隨着時間的推移改善每股經濟效益，並傳達管理層對業務長期價值的信心。</p>
<p>此外，首席執行官 James Nathanielsz 表示，該決定反映了公司對有紀律、靈活的資本配置的承諾。</p>
<p>在盤前交易時，PPCB 的交易價格為 2.87 美元，較納斯達克上漲 114.23%。</p>
<p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
<p>商業新聞</p>

PPCB

<p>Propanc Biopharma 的董事會批准了一項 500 萬美元的股票回購計劃。該公司旨在增加股東的持股比例，並傳達對長期價值的信心。首席執行官 James Nathanielsz 提到要進行有紀律的資本配置。在公告發布後，PPCB 股票在盤前交易中上漲超過 114%，達到了 2.87 美元</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作為您在 Google 上的首選新聞來源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Thursday, Propanc Biopharma, Inc. (PPCB) announced that its board has approved a share repurchase program, authorizing the company to repurchase up to $5.0 million of its common stock.</p>
<div class="lb-trans"><p>週四，Propanc Biopharma, Inc. (PPCB) 宣佈其董事會已批准一項股票回購計劃，授權公司回購最多 500 萬美元的普通股。</p>
</div><p>The company expects the program to allow the shareholders to continue to increase their ownership in its underlying assets, improve per share economics over time, and signal management's confidence in the long-term value of the business.</p>
<div class="lb-trans"><p>公司預計該計劃將使股東能夠繼續增加對其基礎資產的擁有權，隨着時間的推移改善每股經濟效益，並傳達管理層對業務長期價值的信心。</p>
</div><p>Moreover, CEO James Nathanielsz stated that the decision reflects the company's commitment to disciplined, flexible capital allocation.</p>
<div class="lb-trans"><p>此外，首席執行官 James Nathanielsz 表示，該決定反映了公司對有紀律、靈活的資本配置的承諾。</p>
</div><p>In the pre-market hours, PPCB is trading at $2.87, up 114.23 percent on the Nasdaq.</p>
<div class="lb-trans"><p>在盤前交易時，PPCB 的交易價格為 2.87 美元，較納斯達克上漲 114.23%。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商業新聞</p>
</div>

Propanc Biopharma 董事會批准了 500 萬美元的股票回購計劃，該公司股價在盤前交易中上漲